5-Amino-1MQ FAQ

What is 5-Amino-1MQ?

5-Amino-1MQ (full chemical name: 5-Amino-1-Methyl-Quinolinium) is a synthetic small-molecule compound that functions as a selective inhibitor of nicotinamide N-methyltransferase, commonly abbreviated as NNMT. This research chemical was first synthesized and characterized for its ability to modulate cellular energy metabolism through inhibition of the NNMT enzyme, which plays a critical role in the NAD+ salvage pathway.

The compound exists as a salt form, typically supplied as 5-Amino-1MQ chloride or in related salt variations. As a quaternary ammonium compound with hydrophilic properties, it demonstrates relatively good bioavailability when administered via subcutaneous injection. Research interest in 5-Amino-1MQ has grown significantly among the peptide research community due to its purported effects on metabolic regulation and body composition.

How Does 5-Amino-1MQ Work?

5-Amino-1MQ operates through inhibition of the NNMT enzyme, which catalyzes the methylation of nicotinamide using S-adenosylmethionine (SAM) as the methyl donor. By blocking NNMT activity, 5-Amino-1MQ redirects nicotinamide metabolism toward the salvage pathway, increasing NAD+ production. This increased NAD+ availability activates sirtuins and poly(ADP-ribose) polymerase (PARP), cellular proteins involved in energy metabolism, DNA repair, and mitochondrial function.

Elevated NAD+ levels enhance oxidative phosphorylation efficiency in mitochondria, potentially improving ATP production and cellular energy status. In adipose tissue, NNMT inhibition may reduce the formation of metabolically inactive white adipose tissue and promote browning of adipocytes. The enhanced metabolic activity in brown and beige adipocytes increases energy expenditure through thermogenesis, contributing to the reported fat-loss effects observed in research contexts.

What Are Common Dosing Protocols?

Subcutaneous injection remains the predominant administration route in research settings. Typical subcutaneous dosing ranges from 150 mcg to 500 mcg per injection, with many researchers administering once or twice daily. The dosing frequency and total daily dose vary considerably based on individual tolerance, goals, and research protocols. A standard approach involves starting at the lower end of this range and titrating upward based on tolerance and response.

For oral administration, dosages typically range from 50 mg to 100 mg daily, though oral bioavailability may be lower than subcutaneous administration due to first-pass hepatic metabolism. Cycle length in research protocols generally spans 4 to 12 weeks, with many researchers implementing 8-week cycles followed by off-cycle periods. The lack of established human pharmacokinetic data means dosing recommendations are based on anecdotal reports and preclinical research rather than clinical trials.

What Side Effects Have Been Reported?

Preclinical studies have consistently demonstrated favorable tolerability profiles for 5-Amino-1MQ in rodent models at research doses. No major adverse events were documented in published animal research, with treated animals showing normal organ function and histology. However, human safety data remains extremely limited, and long-term effects in humans have not been systematically evaluated.

Anecdotal reports from research communities mention transient injection site reactions (mild redness or irritation), potential appetite suppression in some individuals, and rare reports of headache or mild gastrointestinal discomfort. The absence of clinical trial data means the true incidence and nature of side effects in humans remain unknown. Any compounds of this class carry inherent risks associated with their research-only status and lack of regulatory oversight.

Is 5-Amino-1MQ Safe?

5-Amino-1MQ has demonstrated a preliminary favorable safety profile in preclinical research models. Published toxicology studies in rodents showed no significant organ toxicity or adverse histopathological findings at research doses, and the compound does not appear to induce mutagenicity in standard genotoxicity assays. However, "preclinical safety" does not equate to human safety.

The critical limitation is the absence of controlled human clinical trials. No Phase 1, Phase 2, or Phase 3 human studies have been published for 5-Amino-1MQ as of 2026. The compound remains a research chemical not approved for human use by any regulatory agency, including the FDA, EMA, or Health Canada. Individuals considering use must understand they are engaging in self-directed research with an unvalidated compound, and potential long-term health consequences remain entirely unknown.

Is 5-Amino-1MQ Legal?

5-Amino-1MQ is not scheduled as a controlled substance in most jurisdictions, including the United States, United Kingdom, Canada, and European Union countries. It is classified as a research chemical and is legally available for purchase from chemical suppliers and specialized peptide vendors in many regions. However, legality does not imply safety or regulatory approval for human consumption.

The legal status specifically designates 5-Amino-1MQ for laboratory or research use only, not for human ingestion or therapeutic application. Some countries may have import restrictions or specific regulations around research chemical purchasing. Athletes competing in sport organizations with anti-doping policies should note that WADA (World Anti-Doping Agency) has not explicitly banned 5-Amino-1MQ as of 2026, but other governing bodies may have different policies. Verification with relevant sports authorities is recommended before competitive use.

Can 5-Amino-1MQ Be Stacked with Other Peptides?

Many researchers combine 5-Amino-1MQ with other metabolic peptides and compounds, including GLP-1 receptor agonists (semaglutide, tirzepatide), other NAD+-boosting compounds, and standard fitness protocols. Theoretical combinations exist that could enhance metabolic effects, such as stacking with MOTS-c (a mitochondrial-derived peptide) to amplify NAD+ metabolism benefits.

However, no published human studies examine safety or efficacy of such stacks. Potential drug interactions are unknown, and synergistic effects remain theoretical. Researchers considering stacking should understand they are operating in an area with zero clinical guidance. The risk profile compounds with each additional experimental agent added to a protocol.

How Should 5-Amino-1MQ Be Stored?

Lyophilized powder should be stored in a cool, dry place, ideally at 2-8°C (36-46°F) in airtight, light-protected containers. Reconstituted solutions containing 5-Amino-1MQ should be refrigerated at 2-8°C and used within the stability window, typically 2-4 weeks depending on the reconstitution medium. Bacteriostatic water is the standard diluent for reconstitution, providing antimicrobial protection for multi-dose vials.

Light exposure and temperature fluctuations degrade the compound. Proper storage directly affects compound potency and safety. Freezing reconstituted solutions is not recommended as repeated freeze-thaw cycles may degrade the peptide. Researchers should maintain detailed storage records and discard any solutions showing signs of contamination, discoloration, or particulate matter.

What Is the Expected Results Timeline?

Anecdotal reports suggest initial subjective effects (improved energy, reduced appetite) may appear within the first 1-2 weeks of use. More significant body composition changes typically require 4-8 weeks of consistent use combined with appropriate diet and exercise. Maximum effects may take 8-12 weeks to manifest, though individual variation is substantial and data remains purely anecdotal.

Factors affecting timeline include baseline metabolic rate, diet adherence, training intensity, individual genetics, dose used, and prior use of similar compounds. The lack of controlled research means these timelines are estimates based on community reports rather than validated clinical data. Expectations should remain conservative, and improvement may be slower than anecdotal accounts suggest.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

Frequently Asked Questions